Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Study Evaluating the Pregnancy Outcomes of Interrupting Endocrine Therapy for Women with Breast Cancer
The purpose of this study is to determine whether having a child after temporarily stopping endocrine treatment is feasible and safe in patients with a hormone receptor-positive early breast cancer. The study will look at whether a temporary interruption of endocrine therapy, with the goal of pregnancy and then resuming endocrine therapy to complete a standard course, is associated with a higher risk of breast cancer recurrence. The study will also assess the success of pregnancy, the health of the newborn, and the patient’s ability to breastfeed.
In order to participate you must meet the following criteria:
- Are between 18 and 42 years of age at enrollment.
- Have received adjuvant endocrine therapy (SERM alone, GnRH analogue plus SERM or AI) for ≥18 months but ≤30 months for early breast cancer.
- Wish to become pregnant.
You will be excluded from the study if any of the following criteria apply to you:
- Are post-menopausal at breast cancer diagnosis.
- Have current local, loco-regional relapse and/or distant metastatic breast cancer.
- Have concurrent disease or condition that would make you inappropriate for study participation or any serious medical disorder that would interfere with your safety.
This is a partial list of inclusion and exclusion criteria.